Navigation Links
Oppenheimer's Investment Bank Continues Expansion -- Lance Alstodt Named Managing Director - Healthcare
Date:10/7/2009

NEW YORK, Oct. 7 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings, is pleased to announce that Lance Alstodt will join the firm as Managing Director in Healthcare in the firm's burgeoning Investment Banking area. He will report to Brian McCarthy, Oppenheimer's Head of Healthcare Investment & Corporate Banking.

"Lance is an experienced and very capable senior banker in the medical technology space. He will be a real driver of our medical technology effort and is an important addition to the firm," said Brian McCarthy.

Lance joins Oppenheimer from Bank of America Merrill Lynch, where he worked in both the Global Mergers & Acquisitions and Global Healthcare Investment Banking Groups, generating and executing financing and advisory transactions in the Medical Technology sector.

Before moving to Bank of America Merrill Lynch, Lance had worked in the Global Mergers and Acquisitions Group at JP Morgan Chase, with a focus on Healthcare.

"Medical technology is an important piece of our Healthcare investment banking practice and we view Lance as a highly strategic hire and we're delighted he has joined us," said Marshall Heinberg, Oppenheimer's Head of Investment & Corporate Banking.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.


'/>"/>
SOURCE Oppenheimer & Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
7. Cord Blood America Continues to Reduce Debt; Three Notes Retired
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. TMS Health Continues to Expand - Adding Over 60 New Jobs at Boca Raton Headquarters
10. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced ... report to their offering. ... , The report provides separate comprehensive ... , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... DrugDev ... announcement that it is one of the early adopters completing EU-U.S. Privacy Shield Certification ... designed to provide companies on both sides of the Atlantic with a mechanism to ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... celebrating the passage of the most comprehensive mental health systems reform legislation in ... support of the President, and the commitment of our elected officials to improving ...
(Date:12/7/2016)... York, NY (PRWEB) , ... December 07, 2016 ... ... amounts of the drug in their bodies, a researcher at the Icahn School ... journal Pediatric Research. , The study found that when young children are exposed ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of Smart Device Remote Control through a new partnership with Splashtop Inc. This ... strengthens its mobile solutions to help businesses maximize their uptime and productivity. , ...
Breaking Medicine News(10 mins):